Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 11Multiple Myeloma 7Sarcoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Ovarian Neoplasms 2Neurofibrosarcoma 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Congenital Abnormalities 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1

Interventions

Cyclophosphamide 6Filgrastim 5Etoposide 5fludarabine 4Temozolomide 4Granulocyte Colony-Stimulating Factor 4Carboplatin 4Thiotepa 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Automobiles 3tazemetostat 2sargramostim 2ribociclib 2fludarabine phosphate 2Vorinostat 2Vincristine 2Topotecan 2Sirolimus 2Mesna 2Busulfan 2veliparib 1trametinib 1thymoglobulin 1sonidegib 1selinexor 1reolysin 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Rhabdoid Tumor × selinexor × Clear all
NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

St. Jude Children's Research Hospital

Phase 1 Withdrawn
CNS

Central Nervous System Neoplasms, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡